Ingrid Glimelius

Ingrid Glimelius is a professor of Oncology and a Senior Consultant in Oncology at Uppsala University Hospital in Sweden. She regularly cares for and treats patients with all types of lymphomas. She is a principal investigator in several ongoing clinical trials, including bi-specific antibodies, novel targeted drugs, and CAR-T cells.

Ingrid Glimelius has been a professor of Oncology at Uppsala University since 2022, with a strong research focus on malignant lymphoma. The studies span from optimising treatments, exploring cancer survivorship, and studying the difficult relationship between pregnancy and cancer. Her unique niche is within clinical cancer epidemiology. She is also a principal investigator in Uppsala in several ongoing clinical trials (phase I, II, III, and IV).

Her unique niche is clinical cancer epidemiology.
With her knowledge from clinical work as a physician, she can raise clinically relevant questions, primarily in the field of lymphoma. She has addressed prognostic research questions, investigated disease risks, and studied late adverse effects of treatment using data from national and other registers in the Nordic countries. She has investigated the long-term adverse effect of chemo- and/or radiotherapy, mainly for young Hodgkin lymphoma patients, where we now see that it is the chemotherapy that presently causes the majority of side effects.